Inhibikase Therapeutics (IKT) EBIT Margin (QoQ) (2020 - 2023)

Inhibikase Therapeutics (IKT) EBIT Margin (QoQ) (2020 - 2023) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Inhibikase Therapeutics 55.25 Mn -115.12 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2023 -44.04 Bn
Sep 30, 2023 -66,532.00
Jun 30, 2023 197,955.00
Mar 31, 2023 -48,798.00
Dec 31, 2022 5.51 Mn
Sep 30, 2022 891,755.00
Jun 30, 2022 -6.07 Mn
Mar 31, 2022 24.93 Mn
Dec 31, 2021 -25.80 Mn
Sep 30, 2021 -116,839.00
Jun 30, 2021 -627.00
Mar 31, 2021 51,809.00
Dec 31, 2020 105,678.00
Sep 30, 2020 -157,293.00
Jun 30, 2020 1,092.00